Sanofi and Orano Med reported that their lead alpha-emitting radiopharmaceutical candidate, AlphaMedix (also described in Sanofi’s AlphaMedix-02 study), met primary endpoints for overall response rate and safety in a Phase 2 trial of unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). The 61-patient study included cohorts previously treated with Novartis’ Lutathera and those who were Lutathera‑naive; Sanofi said benefits were observed across secondary endpoints including progression‑free and overall survival. Sanofi acquired the asset through a nine‑figure deal; the company signaled the data will underpin regulatory discussions and an upcoming presentation at the European Society for Medical Oncology (ESMO) meeting. The results validate Orano Med’s 212Pb lead platform and strengthen Sanofi’s targeted alpha therapy pipeline, highlighting alpha emitters as a clinical approach distinct from beta-based PRRT. Sanofi and Orano Med emphasized a manageable safety profile and clinically meaningful activity, positioning AlphaMedix as a potential new option for a hard‑to‑treat GEP‑NET population. The companies plan regulatory engagement and further analyses before wider submission filings.